End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
50.17 CNY | +0.34% | -4.73% | -41.68% |
Apr. 29 | MGI Tech Showcases Life Science Excellence At ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer | CI |
Apr. 28 | MGI Tech Co. Ltd. Opens Customer Experience Center in Brazil | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 4.59 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.68% | 2.85B | - | ||
+7.01% | 217B | B | ||
+11.01% | 190B | B- | ||
+19.20% | 143B | B- | ||
+30.79% | 111B | A- | ||
+1.48% | 64.59B | A- | ||
+13.95% | 52.36B | B+ | ||
-0.16% | 48.45B | B+ | ||
-6.20% | 38.03B | A | ||
+0.91% | 35.61B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688114 Stock
- Ratings MGI Tech Co., Ltd.